company background image
GOV logo

Insulet DB:GOV Stock Report

Last Price

€268.10

Market Cap

€18.8b

7D

1.2%

1Y

43.3%

Updated

19 Jan, 2025

Data

Company Financials +

Insulet Corporation

DB:GOV Stock Report

Market Cap: €18.8b

GOV Stock Overview

Develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. More details

GOV fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance5/6
Financial Health5/6
Dividends0/6

Rewards

Earnings are forecast to grow 5.85% per year

Earnings grew by 250.8% over the past year

Risk Analysis

Has a high level of debt

Significant insider selling over the past 3 months


My Notes

Capture your thoughts, links and company narrative

Insulet Corporation Competitors

Siemens Healthineers

XTRA:SHL

€58.4b

Carl Zeiss Meditec

XTRA:AFX

€4.2b

Eckert & Ziegler

XTRA:EUZ

€1.0b

Drägerwerk KGaA

XTRA:DRW3

€959.0m

Price History & Performance

Summary of share price highs, lows and changes for Insulet
Historical stock prices
Current Share PriceUS$268.10
52 Week HighUS$268.10
52 Week LowUS$147.20
Beta1.22
1 Month Change9.43%
3 Month Change23.15%
1 Year Change43.25%
3 Year Change36.47%
5 Year Change54.08%
Change since IPO2,241.48%

Recent News & Updates

Recent updates

Shareholder Returns

GOVDE Medical EquipmentDE Market
7D1.2%1.5%2.6%
1Y43.3%-6.0%13.4%

Return vs Industry: GOV exceeded the German Medical Equipment industry which returned -6% over the past year.

Return vs Market: GOV exceeded the German Market which returned 13.4% over the past year.

Price Volatility

Is GOV's price volatile compared to industry and market?
GOV volatility
GOV Average Weekly Movement4.6%
Medical Equipment Industry Average Movement6.5%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.5%
10% least volatile stocks in DE Market2.4%

Stable Share Price: GOV has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: GOV's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20003,000Jim Hollingsheadwww.insulet.com

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company’s Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally.

Insulet Corporation Fundamentals Summary

How do Insulet's earnings and revenue compare to its market cap?
GOV fundamental statistics
Market cap€18.83b
Earnings (TTM)€409.58m
Revenue (TTM)€1.93b

46.0x

P/E Ratio

9.8x

P/S Ratio

Is GOV overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GOV income statement (TTM)
RevenueUS$1.98b
Cost of RevenueUS$595.20m
Gross ProfitUS$1.39b
Other ExpensesUS$967.80m
EarningsUS$420.90m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 20, 2025

Earnings per share (EPS)6.00
Gross Margin70.00%
Net Profit Margin21.22%
Debt/Equity Ratio123.4%

How did GOV perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/19 15:26
End of Day Share Price 2025/01/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Insulet Corporation is covered by 58 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anand VankawalaAvondale Partners
Jeffrey JohnsonBaird
null nullBaird